research use only

Azenosertib (Zn-C3) Wee1 inhibitor

Name: Azenosertib (Zn-C3)
Brand: Selleck Chemicals
SKU: E1000
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.E1000

Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.

Chemical Structure

Molecular Weight: 526.63

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.81%

99.81

Products Often Used Together with Azenosertib (Zn-C3)

Adavosertib (MK-1775)

Compared to Adavosertib, it has a higher selectivity and better safety profiles, making it particularly well-suited for combination therapies.

lunresertib (RP-6306)

Combined inhibition of WEE1 and PKMYT1 with it and RP-306 exhibits synergism in killing of U2OS cells.

Related Targets	DNA/RNA Synthesis CDK Microtubule Associated Ras HSP PD-1/PD-L1 Aurora Kinase Casein Kinase Rho Serine/threonin kinase eIF Chk ROCK Myc Kinesin PLK DHFR PAK PERK DYRK RUNX PP2A PFKFB AP-1 MPS1 p21 BMI-1 LIM kinase Nur77 APC
Related Products	Adavosertib (MK-1775) PD0166285 Debio 0123 Phospho-Wee1 (Ser642) Antibody [P3A10] lunresertib (RP-6306) Wee1 Antibody [K14K15] Potrasertib

Chemical Information, Storage & Stability

Molecular Weight	526.63	Formula	C₂₉H₃₄N₈O₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2376146-48-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (189.88 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.49mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.49mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Wee1 ^[1] 3.9 nM
References	[1] https://pubmed.ncbi.nlm.nih.gov/34423975/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05743036	Recruiting	Metastatic Colorectal Cancer	K-Group Beta Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc\|Pfizer	February 27 2023	Phase 1\|Phase 2
NCT05682170	Recruiting	Acute Myeloid Leukemia (AML)	K-Group Alpha Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc.	December 1 2022	Phase 1\|Phase 2
NCT05431582	Withdrawn	Tumors\|Ovarian Cancer\|Breast Cancer\|Lung Cancer\|Pancreatic Cancer	M.D. Anderson Cancer Center\|Zentalis Pharmaceuticals	December 14 2022	Phase 1
NCT05198804	Recruiting	Ovarian Cancer\|Platinum-resistant Ovarian Cancer\|Primary Peritoneal Carcinoma\|Fallopian Tube Cancer	K-Group Beta Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc	January 27 2022	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):